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Abstract 
During the last 12 months, COVID-19 became a global problem. Universities and drug companies are 
working together for the development of treatments. Vaccines appear to be one of the most promising 
treatments, and trials are completed, and other are ongoing. All these studies tend to use a common 
comparator, the percentage of vaccine efficacy (VE%), calculated using the following formula VE=(1-RR) 
x100. A recent study published in a renowned medical journal presented large trial results using a different 
formula VE=(1-OR) x100. We compared the analysis using relative risk (RR) versus an odds ratio (OR), and 
we did not find any large difference in the results. Nevertheless, we would advise using RR instead of OR 
in the interests of accuracy, for best practice. 
Text 
Logunov et al. (2021) conducted an interim analysis of a randomised controlled phase 3 trial evaluating 
the safety and efficacy of a vector-based heterologous prime-boost COVID-19 vaccine (1). To calculate the 
vaccine efficacy, they used the following formula: VE=(1-OR) x100. The odds ratio (OR) is calculated by the 
formula OR = ad/bc, where a is the number of cases in the vaccinated arm, b is the number of non-cases 
in the arm,  c is the number of cases in the control group, and d is the number of non-cases in this arm.  
The Department of Epidemiology of the School of Public Health, UCLA, however, suggests that the formula 
for the calculation of the vaccine efficacy is VE=(1-RR) (2), where the relative risk (RR) =[a/(a+c)]/[b/(b+d)]. 
The authors also added that RR must be less than 1 for the vaccination to be preventive. 
Vaccine efficacy has been explained by Hodgson et al. (2020)(3); in simple term, it represents the 
percentage reduction in disease incidence in a vaccinated group compared to a non-vaccinated group 
under optimal conditions. The UCLA definition is consistent with the one provided by Spiegelhalter and 
Masters (4). 
Difference between OR and RR 
RR represents a ratio of the probabilities (p) or risks of an event or outcome across two groups; OR is a 
ratio of the odds of an event or outcome across two groups (5). OR is the ratio of two odds; RR is the ratio 
of two probabilities (P); odds of an event = P/(1-P). 
Recommendations 
We recommend using RR instead of the OR to calculate efficacy because efficacy is the reduction in the 
risk effected by the vaccine. To calculate the log-transformed RR standard errors, we used the formula in 
Altman's Statistics with Confidence (6). We have compared the table in their publication with a table that 
we created using the formula VE=(1-RR) x100. As shown in Table 1, the differences are small. The only 
noticeable discrepancy lies in the lower confidence interval for the >60 groups.  It should be said that with 
the large numbers involved in a clinical trial, the prevalence or risk is low, and in such circumstances OR 
and RR are approximately equal. Nevertheless, we believe that it is important to use the correct formula 
for the calculation to provide not only the best evidence but also for following best practice. 
 
Table 1 Interim results of vaccine efficacy using VE=(1-OR) x 100 (1) vs VE=(1-RR) x 100 
1st occurrence 21 days after dose 1 VE=(1-OR) x 100 VE=(1-RR) x 100 
 Vaccine efficacy % (95% CI) Vaccine efficacy % (95% CI) 
Overall 91·6 (85·6–95·2) 91.5 (85.4, 95.1) 
Age Group   
   18-30 91·9 (51·2–99·3) 91.8 (27.1, 99.1) 
   31-40 90·0 (71·1–96·5)  89.9 (69.2, 96.7) 
   41-50 91·3 (73·7–96·9) 91.3 (73.7, 97.1) 
   51-60 92·7 (81·1–97·0) 92.6 (80.4, 97.2) 
   >60 91·8 (67·1–98·3) 91.7 (61.2, 98.2) 
Sex   
   Female 87·5 (73·4–94·2)  87.3 (72.6, 94.1) 
   Male 94·2 (87·2–97·4)  94.1 (86.8, 97.3) 
Moderate/Severe Cases 100 (94·4–100·0)  100.0 (95.1*,100.0) 
First COVID-19 occurrence after 
dose 1 
  
   Any time after dose 1 73·1 (63·7–80·1) 72.8 (63.4, 79.8) 
   From 14 days after dose 1 87·6 (81·1–91·8)  87.5 (80.9, 91.8) 
First COVID-19 occurrence after 
dose 2 (28 days after dose 1) 
  
All 91·1 (83·8–95·1) 91.0 (83.3, 95.1) 
* To calculate the lower limit, we used the "rule of 3": with zero events out of 14964, an upper bound for the rate 
of occurrences is 3/14964. 
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